|
Date: October 3, 2006
UCLA/VA
Study Finds Chemical Found in Curry May Help Immune System Clear
Amyloid Plaques Found in Alzheimer’s Disease
(click
images for larger version)
(A)
Untreated macrophages bind amyloid beta on the surface. (B)
After curcumin treatment, macrophages ingest and degrade
amyloid beta. Credit: UCLA
|
UCLA/VA researchers found
that curcumin — a chemical found in curry and turmeric —
may help the immune system clear the brain of amyloid beta, which
form the plaques found in Alzheimer's disease.
Published in the Oct. 9 issue
of the Journal of Alzheimer's Disease, the early laboratory
findings may lead to a new approach in treating Alzheimer's
disease by enhancing the natural function of the immune system
using curcumin, known for its anti-inflammatory and anti-oxidant
properties.
Using blood samples from six
Alzheimer's disease patients and three healthy control patients,
the researchers isolated cells called macrophages, which are the
immune system's PacMen that travel through the brain and body,
gobbling up waste products, including amyloid beta.
The team treated the
macrophages with a drug derived from curcumin for 24 hours in a
cell culture and then introduced amyloid beta. Treated
macrophages from three out of six Alzheimer's disease patients
showed improved uptake or ingestion of the waste product compared
to the patients' macrophages not treated with curcumin.
Macrophages from the healthy controls, which were already
effectively clearing amyloid beta, showed no change when curcumin
was added.
"Curcumin improved
ingestion of amyloid beta by immune cells in 50 percent of
patients with Alzheimer's disease. These initial findings
demonstrate that curcumin may help boost the immune system of
specific Alzheimer's disease patients," said Dr. Milan
Fiala, study author and a researcher with the David Geffen School
of Medicine at UCLA and the VA Greater Los Angeles Health Care
System. "We are hopeful that these positive results in a
test tube may translate to clinical use, but more studies need to
be done before curcumin can be recommended."
The patients ranged in age from
65 to 84. Fiala noted that the patients whose immune cells
responded were younger and had higher scores on a Mini-Mental
State Examination suggesting that curcumin may help those with
less advanced dementia. Some of the patients may have already had
additional curcumin in their systems due to participation in
another UCLA study, which may have impacted findings.
"Our next step will be to
identify the factors that helped these immune cells respond,"
said Laura Zhang, a study author and a UCLA/VA research assistant
in Fiala's lab.
Fiala noted that the method
researchers used to test the immune cell response of macrophages
may provide a novel way of evaluating the effectiveness of drugs
in clearing amyloid beta from the brain and may help to
individualize Alzheimer's disease treatment.
According to Fiala, macrophages
are the soldiers of the innate immune system — the part of
the immune system which is present at birth. Curcumin may support
the body's natural immune fighting function in directly helping
macrophages clean away amyloid-beta. The treatment of macrophages
with curcumin is radically different from some of the vaccine
approaches currently being studied.
The study was funded by the
Alzheimer's Disease Association and private donors. The curcumin
derived drug was provided by the Sabinsa Corporation, a company
that manufacturers phytonutrients and specialty chemicals for
nutritional, pharmaceutical and food industries. Fiala
participated in a speaking engagement for Sabinsa.
Other study authors include:
Michelle Mahanian, Justin Zaghi and Mark Rosenthal from the
Department of Medicine, Veterans Affairs Greater Los Angeles
Healthcare System and David Geffen School of Medicine at UCLA;
John Cashman of the Human BioMolecular Research Institute, San
Diego; James Sayre of the Department of Biostatistics, UCLA
School of Public Health; Araceli Espinosa of the UCLA Department
of Neurobiology; Vladimir Badmaev, Applied Pharmacology, Sabinsa
Corporation, New Jersey; Michael C. Graves, UCLA Department of
Neurology; and George Bernard, UCLA Department of Neurology and
Division of Oral Biology and Medicine, UCLA School of Dentistry.
Source
/ Credit: UCLA
|